Filing Overview
This Form 6-K was filed by I-MAB, a foreign private issuer, for October 2021 and signed on October 19, 2021. The filing identifies I-MAB’s principal executive offices in Shanghai, China, and states that the company files annual reports on Form 20-F. The request metadata names “Novabridge Biosciences,” but the filing itself identifies the registrant as I-MAB.
Financial Metrics
The provided filing text contains no financial statements, revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics.
Material Changes
The filing text does not describe material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing is a cover report that lists Exhibit 99.1 as a press release. The contents of the press release are not included in the provided text, so no guidance, outlook, management commentary, risks, contingencies, or unusual items can be assessed.
Investor Verification Items
- Verify the registrant identity, because the supplied metadata names Novabridge Biosciences while the filing names I-MAB.
- Obtain and review Exhibit 99.1, the referenced press release.
- Confirm whether the press release contains financial results, financing information, clinical or business developments, guidance, or risk disclosures.